The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly

Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly

October 9, 2019 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC).

You Might Also Like
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • Anti-CarP May Play Special Role in RA-Associated Mortality
  • Mortality Trends in Lupus Nephritis

“The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells Reuters Health by email. “However, for AAV, we see the opposite trend, with decreasing mortality.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Immunosuppressive therapy has been the mainstay of treatment of active AAV since the 1950s, and a meta-analysis covering 10 studies between 1980 and 2005 suggested that AAV-related mortality had improved.

Dr. Steinberg’s team used data from CDC’s Wide-ranging Online Data for Epidemiologic Research Database to examine contemporary mortality trends of AAV in the U.S.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

From 1999 to 2017, there were 11,316 AAV-related deaths, for an age-adjusted mortality rate of 1.86 per 1 million persons.

The mortality rate per 1 million persons was highest among non-Hispanic whites (2.03 vs. 0.77 for non-Hispanic blacks and 1.57 for Hispanics); among men (2.13 vs. 1.65 among women); among Midwesterners (2.15 vs. 2.01 in the West, 1.70 in the South, and 1.66 in the Northeast); and among persons aged 75 to 84 years.

During this period, the mortality rate decreased by an average of 1.6% per year, with an even greater decrease among patients aged 65 to 74 years (2.5% per year), the researchers report in Annals of Internal Medicine, online Oct. 8.1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Granulomatosis with polyangiitis accounted for 85% of the AAV deaths, and the most common underlying cause of death was the vasculitis itself (64%), followed by cardiovascular disease (12%), cancer (6%) and pulmonary disorders (5%).

Decreasing mortality trends were similar when stratified by sex, race and geographic region.

“We speculate that the decrease in the overall mortality, and mortality particularly among persons aged 65 to 74 years, during the study period may reflect increased longevity due to improved treatment of AAV and common comorbid conditions,” Dr. Steinberg says.

“It is impossible to directly identify causality from mortality data in a way that might guide future therapeutic choices,” he says. “We think the trend toward improving mortality suggests the medical community is working in the right direction and we should continue to strive to diagnose and treat these diseases and their comorbidities. Furthermore, the current mortality level suggests that more clinical research into improved treatment is warranted.”

“We hope physicians reading our research come away with a reminder that these diseases, particularly granulomatosis with polyangiitis, still lead to significant mortality despite improvements,” Dr. Steinberg says. “We also hope to spark curiosity and investigation into what is driving these changes and the trends we demonstrate in regional, ethnic, and age group mortality.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: AAV, GPA, mortality, mortality rate

You Might Also Like:
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • Anti-CarP May Play Special Role in RA-Associated Mortality
  • Mortality Trends in Lupus Nephritis
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.